Article Figures & Data
Figures
- FIGURE 1.
Yearly publication numbers from PubMed for PET/MRI (orange) compared with PET/CT (blue). Dashed lines are corresponding moving averages. PET/MRI showed almost exponential growth until 2015 before flattening of curve. Adjustment of 2021 data is based on projection from data collection point 80% through year.
- FIGURE 2.
Yearly publication numbers for 2020 from PubMed for PET/MRI show that cancer has greatest engagement, followed by brain, other (unlisted applications), cardiac, and pediatric.
- FIGURE 3.
Yearly publication numbers for 2020 from PubMed for PET/MRI for various oncology applications suggest that prostate, brain, and neuroendocrine (including pancreatic) are most significant applications.
- FIGURE 4.
Patient with left ventricular ejection fraction of 30% and inferior-to-posterolateral akinesia on echocardiography. 18F-FDG PET/MRI shows decreased metabolic activity of posterolateral wall (A and D), corresponding to late gadolinium enhancement on MR images (C and F) and confirmed on fused images (B and E). (Reprinted from (31).)
- FIGURE 5.
Poorly differentiated squamous cell carcinoma of cervix on CT (A, left) and PET/CT (A, right), with corresponding unenhanced T2-weighted turbo spin-echo CT (B, left) and T2-weighted turbo spin-echo PET/MRI (B, right) and contrast-enhanced sagittal MRI T1-weighted MRI (Dixon–visual background extractor sequence) (C, left) and PET/MRI (C, right). (Reprinted from (32).)
- FIGURE 6.
Simultaneous PET/MRI in dementia using 18F-florbetaben PET and pulsed arterial spin labeling (pASL) MRI. MPRAGE = magnetization-prepared rapid gradient echo. (Reprinted from (33).)
